From the first launch to ongoing market access operational execution, IntegriChain solves some of the most complex and pressing challenges associated with drug commercialization. We deliver pharma’s only comprehensive data, consulting, and business process platform for market access departments, providing the strategy, data, applications, and infrastructure for therapy commercialization.
Solutions overview
IntegriChain delivers the pharmaceutical industry’s largest and only data and business process platform for therapy commercialization and access. Manufacturers rely on our analytics, applications, and managed services to power their operations and harness the value of their channel, patient and payer data.
View all products
IntegriChain provides a complete set of professional services for commercialization and market access execution–from life science strategy and operational consulting to implementation, integration, migrations, and analytics.
Services overview
We help all stakeholders in the pharmaceutical industry drive access with our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts & pricing, gross-to-net, channel, and patient services – to unlock strategic payer, provider, pharmacy and patient access insights.
Learn more about our company
Learn more about joining our growing IntegriChain team of data scientists, market access experts, analysts, and consulting professionals – our culture, our purpose, our teams in the US and Pune. Check out our careers or keep in touch for future opportunities.
Careers overview
OnDemand
As more states adopt drug pricing transparency laws to help lower the cost of prescription drugs, pharmaceutical manufacturers, especially those about to launch their first therapy, must understand the changing legal landscape and what it means for their business now and in the future.
In this informative discussion, Rupal Patel, Director of Advisory Services, and John Whitridge, Senior Advisory Services Consultant discuss the current state of drug pricing transparency laws, including:
Rupal Patel John Whitridge Please fill out the form to listen to the discussion.
To download our datasheet detailing solutions to reduce compliance risk around state price transparency, click here.
